Hi all,
Now they have started a new trial for low risk MDS patients with anemia.
The drug is a monoclonal antibody called Siltuximab and is targeting Interleukin-6 that acts as both a pro-inflammatory and anti-inflammatory cytokine. It is secreted by T cells and macrophages to stimulate immune response.
It is a multicenter study carried out in 48 locations in many countries.
http://clinicaltrials.gov/ct2/show/N...tuximab&rank=4
Kind regards
Birgitta-A